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Abstract: Thirty four halogen and selenium-containing quinones, synthesized by 
rhodium-catalyzed C-H bond activation and palladium-catalyzed cross-coupling 
reactions, were evaluated against bloodstream trypomastigotes of T. cruzi. We have 
identified nine compounds with IC50/24 h values of less than 2 µM. Electrochemical 
studies on A-ring functionalized naphthoquinones were also performed aiming to 
correlate redox properties with trypanocidal activity. For instance, (E)-5-styryl-1,4-
naphthoquinone 60 and 5,8-diiodo-1,4-naphthoquinone 3, which are around fifty fold 
more active than the standard drug benznidazole, are potential derivatives for further 
investigation. These compounds represent powerful new agents useful in Chagas disease 
therapy. 
 
Keywords: C-H functionalization, Quinones, Chagas disease, Trypanosoma cruzi, 
Electrochemistry. 
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1. Introduction 
 
Chagas disease, caused by Trypanosoma cruzi (T. cruzi), is classified as a 
neglected tropical disease by the World Health Organization. This disease has high 
morbidity and mortality rates, affects 5-7 million people and displays a limited response 
to therapy [1]. It is transmitted to humans by triatomine vectors, blood transfusions, oral 
and congenital routes and less commonly, by organ transplantation, and laboratory 
accidents [2]. Chagas disease is characterized by two clinical phases: a short, acute phase 
defined by patent parasitaemia and a long, progressive chronic phase. The acute phase 
appears shortly after infection and is frequently asymptomatic. After 2 to 3 months, in 
most infected individuals, a host/parasite balance is achieved, leading to the chronic 
phase. Approximately two thirds of infected individuals remain in the indeterminate 
chronic form, but after 10 to 30 years, the other third will develop a symptomatic chronic 
disease with digestive and/or cardiac disturbances [3]. Two current major concerns are 
outbreaks of acute Chagas disease associated with the ingestion of contaminated food [4], 
and the disease’s emergence in non-endemic areas such as North America and Europe, 
due to the immigration of infected individuals [5]. 
T. cruzi is a hemoflagellate protozoan and its life cycle involves distinct forms 
during its passage through vertebrate and invertebrate hosts. The trypomastigote form 
ingested by the insect differentiates into the proliferative epimastigote form, which, on 
reaching the posterior intestine of the insect, differentiates into the metacyclic form. The 
latter, following invasion of vertebrate host cells, undergoes differentiation into the 
amastigote form, which, after several reproductive cycles, transforms into the 
trypomastigote form, responsible for the dissemination of the infection. 
The current treatment for Chagas disease is restricted to two nitroheterocyclic 
drugs, benznidazole (Bz) and nifurtimox (Nif), and their efficacy varies according to the 
phase of the disease, with their effectiveness decreasing with advancement of the 
infection [6]. The major limitations of these drugs are their limited and variable curative 
activity in the established chronic form of the disease and their toxic effects, leading to 
treatment abandonment in several instances [7]. These drawbacks justify the urgent need 
to identify better drugs to treat chagasic patients. In this context, an intensive research 
program has focused upon the search for alternative natural, semi-synthetic and synthetic 
lead compounds [8]. 
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Over the last few years, our group has dedicated efforts to the synthesis and 
identification of novel naphthoquinoidal compounds with potent antiparasitic activity [9]. 
In this context, we have modified the “redox centre” A- and C-rings of lapachones with 
the aim of preparing new bioactive compounds [9c]. For instance, a simple redox centre 
modification of β-lapachone led to a phenazine derivative with trypanocidal activity about 
two and six times higher than benznidazole and the original quinone, respectively [10]. 
Intrinsically related to this strategy, we have demonstrated that appendage of a triazole 
group to the C-ring of β-lapachone affords a derivative four times more active against the 
parasite than the naphthoquinoidal precursor [11]. Recently, Lim and co-workers [12] 
described the synthesis and evaluation of A-ring modified lapachones, which show 
activity against cancer cells (Scheme 1A); this study is of direct relevance to the strategies 
outlined herein. 
Salomão and co-workers have reported the trypanocidal activity of C-2 and C-5 
substituted naphthoquinones, as well as evidence for their mode of action [13]. As shown 
in Scheme 1B, in assays performed in the absence of blood and with incubation at 37°C 
several compounds presented IC50 values of < 2 µM against T. cruzi. For instance, further 
assays with 5-acetoxy-1,4-naphthoquinone (IC50 = 0.16 µM) revealed activity against the 
proliferative forms of T. cruzi, intracellular amastigotes and epimastigotes. In 
experiments with this latter parasite form, this compound led to mitochondrial swelling, 
vacuolization, and flagellar blebbing, as well as a remarkable decrease in the 
mitochondrial membrane potential and a discrete increase of ROS production. Such redox 
dependent effects are likely reliant on the acetyl group facilitating quinone reduction, as 
previously demonstrated by electrochemical analysis [13b]. These results show that A-
ring substituted naphthoquinones can kill T. cruzi and highlight the importance of 
synthesizing and evaluating new quinoidal compounds against parasites. 
Recently, our group has embarked on a research program aimed at addressing 
unmet synthetic challenges related to quinone modification. For instance, we have 
demonstrated that chiral squaramide catalyzed reaction of lawsone with Morita-Baylis-
Hillman acetates of nitroalkenes leads to the asymmetric formation of 
pyranonaphthoquinones [14]. We have also developed C-H activation-based processes 
that achieve challenging bond formations and enable late stage functionalization of 
complex systems [15]. For example, we reported recently a method for the A-ring 
functionalization of naphthoquinones that is reliant on a rhodium-catalyzed C-5 selective 
C-H iodination reaction [16]. In this report, we outline the C-H functionalization enabled 
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synthesis of 30 quinoidal derivatives and their evaluation against T. cruzi. Four 
compounds were also prepared by C-C bond forming reactions achieved via palladium 
catalysis. Since the biological activity of quinones is intrinsically related to the quinoidal 
redox centre, we also describe the electrochemical behavior of nine representative 
compounds. 
 
 
 Scheme 1. Overview. 
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2. Results and Discussion 
2.1 Chemistry 
 
 Naphthoquinone derivatives were the first class of compounds targeted for 
preparation. A-ring modifications were performed utilizing a carbonyl directed Rh-
catalyzed C-H bond activation protocol reported recently by our group [16]; this 
methodology allowed C-5 selective iodination of several 1,4-naphthoquinones. In the 
simplest case, using 1,4-naphthoquinone (1) as substrate, the synthesis of mono-iodinated 
product 2 occurred in 69% yield, accompanied by a 5% yield of bis-iodinated by-product 
3 (Scheme 1). For the purpose of clarity the numbering system shown in Scheme 1 is used 
during further discussion. 
 
 
Scheme 1. Iodinated naphthoquinoidal derivatives 2 and 3. 
 
Iodinated naphthoquinones containing electron donating and withdrawing groups 
were selected for subsequent biological evaluation. The use of hydroxyl A-ring-
substituted substrates (e.g. 4) changed the regioselectivity of iodination to afford 5, where 
functionalization had occurred ortho to the hydroxyl group (C7) rather than at C5; this 
demonstrates that the carbonyl-directed pathway can be overridden by strong donor 
substituents. Control experiments showed that in the absence of the Rh-catalyst only 
traces of product were observed. Use of 250 mol% NIS enabled subsequent C5 iodination 
of 5 to provide 6 in 82% yield. Reaction of plumbagin 7 with 100 mol% NIS provided 
C7 iodination product 8 in 85% yield. Juglone (4) and plumbagin (7) were reacted with 
iodomethane and Ag2O in CHCl3 to afford 9 and 10 in 73% and 78% yield, respectively 
[17]. Rh-catalyzed C-H iodination of these substrates gave 11 and 12 in excellent yields. 
To prepare compounds containing methoxy groups in different A-ring positions, 
derivatives 5 and 8 were also methylated to afford 13 and 14 in 91% and 92% yield, 
respectively (Scheme 2).  
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Scheme 2. Iodinated A-ring substituted naphthoquinones 5, 6, 8 and 11-14. 
 
Other substrates containing methoxy groups were obtained in good yields by 
oxidation of tetralones 15 and 16 with 2-iodo-benzoic acid and Oxone (substrates 17 and 
18) [18]. When the C-H iodination methodology was applied to these substrates 
derivatives 19 and 20 were generated in good to excellent yields. The regioselectivity 
observed for the iodination of 19 is suggestive of secondary coordination of the methoxy 
group to the Rh-center, thereby facilitating functionalization at the most hindered A-ring 
position (Scheme 3). Consistent with this assertion, iodination of compound 21, in which 
the methoxy group of 19 has been replaced by a methyl substituent, occurred selectively 
at the less hindered position to generate 22 in 63% yield (Scheme 4). 
 
 
Scheme 3. Preparation of iodinated derivatives 19 and 20 from tetralones. 
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Scheme 4. Synthesis of iodinated quinone 22. 
 
 In order to investigate the effects of other electron donating groups, iodination of 
24, which contains an amino group, was pursued. Consistent with hydroxy containing 
systems 4 and 7, functionalization occurred at C-7 to afford 25 in 41% yield and with 
high selectivity. On other hand, iodination of 27, which contains an electron withdrawing 
ester at C-8, was selective for C-5, affording derivative 28 in 57% yield (Scheme 5). Note 
that Ivashkina and co-workers [19] have described the synthesis of 25 using I2-HIO3 but 
the product was obtained as mixture of C-5 and C-7 iodinated products.  
 
 
Scheme 5. Iodinated compounds 25 and 28 prepared from 23 and 26. 
 
Electron deficient naphthoquinones were also used as substrates, affording the 
targets in moderate to good yields. Interestingly, unsymmetrical substrate 29 delivered 30 
(59% yield) as the sole product, indicating that the bromine substituent controls the 
relative directing ability of the two carbonyl groups for the metalation event (Scheme 6). 
 
Scheme 6. Iodinated naphthoquinoidal derivatives 30, 32 and 34. 
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 We also sought to investigate the biological effects of substituents on other 
quinone-based systems. The evaluation of heteroatom substituted benzoquinoidal 
compounds as potential trypanocidal agents was particularly attractive because these can 
be accessed directly by our reported C-H functionalization protocol (Scheme 3) [20]. Rh-
catalyzed reaction of 1,4-benzoquinone 35 with 1,3-diiodo-5,5-dimethylhydantoin (DIH) 
yielded derivative 36 in 95% yield. Exchanging the electrophile source to 1,3-dibromo-
5,5-dimethylhydantoin (DBH) afforded 37 in 82% yield. C-H phenylselenation processes 
were also investigated. Reaction of 35 with 150 mol % N-(phenylseleno)phthalimide 
afforded a mixture of target 38 and bis-functionalization product 39. However, it was 
found that by using only 100 mol% N-(phenylseleno)phthalimide, 38 could be obtained 
in good yield and with high selectivity over 39 (4.5:1 selectivity). The latter compound 
could be accessed exclusively in 74% yield by using an excess (250 mol %) of N-
(phenylseleno)phthalimide (Scheme 7). 
 
 
Scheme 7. Chalcogenated 38 and 39 and iodinated derivatives 35 and 36. 
 Rh-catalyzed iodination of alkyl-substituted system 40 afforded target 41 in 66% 
yield and good regioselectivity. Here, iodination occurs at the site remote to the bulky 
tert-butyl group. A similar result was obtained for bromination of 40 to deliver 42 in 57% 
yield (Scheme 8).  
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Scheme 8. Synthesis of iodinated quinone 41 and brominated one 42 from 40. 
 
 The metal-catalyzed protocol was also applied to benzoquinone 46, containing 
two adjacent methyl groups, and this afforded 49 in 81% yield. Interestingly, attempted 
bromination of 46 lead to degradation. For benzoquinone 47, which contains an electron-
donating methoxy-group, iodination occurred at the most electron rich position to afford 
50 in 91% yield. Bis-iodination of bis-methoxy system 48 was achieved in high yield by 
using an excess of DIH to generate 51 in 76% yield (Scheme 9). 
 
 
 
Scheme 9. Iodinated quinoidal derivatives. 
 
 Systems possessing electron-withdrawing substituents proved to be more 
challenging; for example, electron deficient substrate 52 reacted smoothly with DIH to 
provide 53 in 56% yield. Bromination of 52 provided 54 in only 45% yield (Scheme 10). 
 
 
Scheme 10. Preparation of iodinated derivative 53 and brominated 54 from electron 
deficient compound 52. 
 
 As outlined in Scheme 11, application of the C-H functionalization conditions to 
1,4-naphthoquinone 1 provided derivatives 55 and 56 in excellent yields and high 
selectivity. The use of [RhCptCl2]2 in combination with CuSO4 was required to achieve 
C-2 rather than C-5 selectivity (cf. Scheme 2). This aspect is notable because site-
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selective C-H functionalization of naphthoquinones (C-2 versus C-5) is achieved under 
catalyst control (cf. Scheme 1). 
 
 
Scheme 11. C-2 substituted naphthoquinones 55 and 56. 
 
 Because iodination of 1,4-naphthoquinone was readily achieved, subsequent 
palladium-catalyzed C-C bond forming derivatizations also became accessible (Scheme 
12), thereby providing an avenue for the synthesis of different classes of hybrid 
quinonoid-based compounds. Under highly optimized conditions,[21] Stille coupling of 
2 afforded 57 in 75% yield. Heck alkenylations [22] of 2 with ethyl acrylate and styrene 
proceeded smoothly to provide 58 and 59, respectively. Several Sonogashira cross-
coupling protocols were evaluated without success. To solve this problem, a previously 
reported procedure [23] was employed, wherein reaction of 2 with an alkynyl-copper(I) 
reagent provided Sonogashira-like product 60 in 64% yield. 
 
 
Scheme 12. Derivatization of 2 via palladium catalyzed C-C bond formatting reactions. 
 
The structures of novel compounds 5, 6, 8, 13, 14, 25, 49 and 59 were determined 
by 1H, 13C and 2D NMR analysis in combination with either electrospray ionization or 
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electronic impact mass spectrometry. Additionally, compounds 5, 6 and 51 were analyzed 
by single crystal X-ray diffraction, as summarized below. 
 
2.2. X-ray analysis 
 
Compound 5 crystallizes in space group P21/c with four independent molecules in 
the asymmetric unit where two of them are superimposed with occupational disorder on 
some atoms. For clarity, only one molecule is shown in Figure 1. The molecule is 
perfectly planar (r.m.s. deviation = 0.0029 A° for 14 non-hydrogen atoms).  In the packing 
of the crystal, five C-H---O type interactions and three O-H---I type interactions link the 
molecules, forming chains that extend along the [b] axis and parallel to (4 0 4) plane. 
Compound 6 crystallizes in space group P21/n with two molecules in the 
asymmetric unit. For clarity, only one molecule is shown in Figure 1. There are no 
significant conformational differences between them. The molecule is almost planar 
(r.m.s. deviation = 0.0051 A° for I3 non-hydrogen atoms) except the I1 and I2 atoms that 
are out of the mean plane of the rings with deviations of -0.179(3) and 0.137(2) A° 
respectively. In the crystal, molecules are linked by weak interactions C2-H2---O3 
[d(H2···O3) = 2.56(2) Å, \(C2-H2···O3) = 125(4)°], C18-H18---O2 [d(H18···O2) = 
2.42(2) Å, \(C18-H18···O2) = 170(3)°] and O-H---I [d(H···I) = 3.53(2)Å] forming chains 
parallel to the (3 -3 -3) and (3 3 -3) planes.  
Finally, compound 51 crystallizes in space group Pnma. The molecule is 
symmetric where the asymmetric units are C1, C2, C3, C4, C5 I1, O1, O2 and O3. The 
I1, O1 and O3 atoms deviate from the mean plane of the ring by -0.154(2), -0.111(2) and 
-0.388(3) A°, respectively.  The C2-C3-O2-C5 torsion angle of the methoxy group is -
158.2(2)°. In the crystal, the molecules are linked by I---O (methoxy group) teractions [d 
= 3.383(2) A°] resulting in a highly symmetrical arrangement that extends along the [a] 
axis. 
An Ortep-3 diagram of each molecule is shown in Figure 1 and Table 1 lists the 
main crystallographic data for 5, 6 and 51. Packing diagrams for all compounds are 
provided in the Supporting Information File. 
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Figure 1. A projection ORTEP-3 of 5, 6 and 51, showing the atom-numbering and 
displacement ellipsoids at the 50% probability level. 
 
Table 1. Crystal data and structure refinement for compounds 5, 6 and 51.  
Identification code Compound 5 Compound 6 Compound 51 
Empirical formula C10H5IO3 C10H4I2O3 C8H6I2O4 
Formula weight 315.5 425.9 419.9 
Temperature 293(2) K 293(2) K 293(2) K 
Wavelength 0.71073 Å 0.71073 Å 0.71073 Å 
Crystal system monoclinic monoclinic orthorhombic 
Space group P21/c P21/n Pnma 
Unit cell dimensions 
a = 7.7911(6) Å  = 90° a = 8.2431(2) Å = 90° a = 9.5066 (4) Å  = 90° 
b = 27.0192(4) Å  = 93.1(5)° b = 15.1653(4) Å = 92.95(2)° b  = 17.3636 (8)Å  = 90° 
c = 13.5802(12) Å  = 90° c = 16.8525(5) Å = 90° c = 6.3177 (2) Å  = 90° 
Volume 2854.8(9) Å3 2103.9(2) Å3 1698.7 (2) Å
3 
Z 4 8 4 
Density (calculated) 2.17 Mg/m3 2.69 Mg/m3 2.67 Mg/m
3 
Absorption coefficient 3.6 mm-1 5.9 mm-1 6.01mm-1 
F(000) 1756 1552 768 
Theta range for data collection 1.7 to 27.9° 1.8 to 27.1° 2.3 to 27.9° 
Index ranges 
-9≤h≤10, -35≤k≤35, 
-13≤l≤17 
-10≤h≤10,  -19≤k≤19, 
-21≤l≤21 
−12≤h≤12, −22≤k≤22, −8≤l≤8 
Collected  Reflections 25651 16620 8822 
Absorption correction none none none 
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2 Full-matrix least-squares on F2 
Data / restraints / parameters 5975 / 0 / 448 3421 / 0 / 273 1241 /0 / 71 
Goodness-of-fit on F2 1.34 1.004 1.21 
Final R indices [I>2sigma(I)] R1 = 0.074, wR2 = 0.15 R1 = 0.037, wR2 = 0.062 R1 = 0.014, wR2 = 0.034 
R indices (all data) R1 = 0.084, wR2 = 0.152 R1 = 0.064, wR2 = 0.069 R1 = 0.015, wR2 = 0.034 
 
2.3. Biological Studies 
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 The potential of simple structural modifications for increasing antiparasitic 
activity of naphthoquinones is shown in Scheme 6. Juglone, a naturally occurring 
naphthoquinone, displays an IC50/24 h value of 6.51 µM [13a]. We have previously 
reported that the addition of methyl or bromine groups to C-5 and/or C-7 leads to new 
naphthoquinones that are 4.7 and 5.2 times more active against T. cruzi than juglone, 
respectively. Remarkably, a 40 fold increase in activity is observed for the O-acetoxy 
derivative of juglone [13a] (Scheme 13). 
 
 
Scheme 13. Simple modifications in juglone leading to compounds with potent 
trypanocidal activity. *IC50/24 h values for the lytic activity on bloodstream 
trypomastigotes. 
 
 Considering these previous results and recent reports in the literature [24,25], we 
have accomplished modifications to the quinoidal system leading to A-, B-, or A- and B-
ring substituted compounds, and these were assayed against T. cruzi. Note that direct 
functionalization by rhodium-catalyzed C-H bond activation allows the efficient and fast 
preparation of potent quinoidal compounds, as shown in Scheme 14. 
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Scheme 14. Strategies for the synthesis of novel trypanocidal naphthoquinones and 
benzoquinones. 
 
Compounds were evaluated against bloodstream forms of T. cruzi (IC50/24 h) and 
mammalian cells (LC50/24 h), allowing the determination of the selectivity index (SI) 
derived from the ratio of LC50/IC50 (Table 2). From these 34 compounds, 22 are more 
active than benznidazole, the reference drug (IC50/24 h = 9.68 ± 2.35 µM), with 2, 3, 13, 
14, 19, 20, 2l, 22, 25, 28, 51, 55, 56, 57 and 59 exhibiting IC50/24h values lower than 2 
µM, with an SI of between 7.5 and 62.5. 
Compounds 2 and 3 show significant activity against the parasite with IC50 values 
of 0.59 and 0.22 µM, respectively, low toxicity for the mammalian cell, and an SI higher 
than 19. Diiodinated naphthoquinone 3 was obtained as a by-product (vide supra) in poor 
yield (5%) and further optimization of its preparation will be necessary. In general, the 
presence of iodine and electron donating groups on the A-ring increases activity against 
T. cruzi and highlights the importance of our Rh-catalyzed C-H iodination methodology. 
Compounds 22 (IC50 = 0.49 µM, SI 24.7) and 25 (IC50 = 0.56 µM, SI 23.4), which 
combine either a methyl or amino group with an iodine substituent, show important 
activity, being around 20 times more active than benznidazole. As such, 22 and 25 are 
prototypes that warrant further study. Conversely, the presence of electron withdrawing 
groups on A-ring and, in some cases, a methyl group leads to decreased activity against 
T. cruzi [34 (7.26/SI 3.8), 12 (7.57/SI 6.9) and 11 (4.06/SI 6.1)]. 
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Certain benzoquinones also show interesting trypanocidal activity, with an IC50 
value of less than 2 µM determined for compound 51. This compound is easily obtained 
from commercially available benzoquinone in just one-step. C-2 functionalization may 
be a good general strategy for preparing bioactive compounds, since naphthoquinones 
substituted at C-2 with iodine (5 IC50 = 1.79 µM, SI 8.2) and selenium (56, IC50 = 1.13 
µM, SI 11.2) were 5.4 and 8.5 times more active than benznidazole, respectively. 
Finally, the most active compound (E)-5-styryl-1,4-naphthoquinone 59 was 
prepared in two steps and is described here for the first time. The synthesis of 59 requires 
C-5 iodinated compound 2, which is prepared by Rh-catalyzed C-H functionalization. 
The C-I bond then enables Pd-catalyzed alkenylation with styrene to afford 59. This 
compound, with an IC50/24h = 0.19 µM, is fifty fold more active than benznidazole, with 
an SI of 62.5. Although the studies described here are preliminary, it is worth noting that 
the combination of a practical synthetic route, high in vitro trypanocidal activity and low 
toxicity to mammalian cells, makes 59 a very attractive hybrid quinone in the search for 
better trypanocides. 
 
Table 2. Activity of synthetic derivatives against bloodstream trypomastigotes of T. 
cruzi (Y strain) at 37 °C, cytotoxicity to mammalian cells and Selectivity Index (SI). 
 
Compd IC50/24h (µM) LC50/24h (µM) SI 
2 0.59  ±  0.08 11.49 ± 0.54 19.5 
3 0.22  ±  0.07 12.93 ± 1.43 28.8 
5 42.0  ±  3.11 > 100 > 4.6 
6 24.8  ±  4.49 > 100 > 5.1 
8 0.99 ± 0.12 15.72 ± 3.49 15.8 
11 3.54  ±  0.71 13.59 ± 0.79 3.8 
12 7.57  ±  0.56 51.88 ± 10.42 6.9 
13 1.35  ±  0.43 13.27 ± 1.73 9.8 
14 4.06  ±  0.47 24.67 ± 6.51 6.1 
19 1.17  ±  0.23 14.19 ± 3.21 12.1 
20 1.62  ±  0.34 12.16 ± 0.16 7.5 
22 0.49  ±  0.04 12.09 ± 0.24 24.7 
25 0.56  ±  0.05 13.12 ± 1.16 23.4 
28 1.61  ±  0.44 13.94 ± 0.21 8.7 
30 1.38  ±  0.57 12.15 ± 0.15 8.8 
32 2.25  ±  0.48 11.82 ± 0.37 5.3 
34 7.26  ±  1.41 27.83 ± 5.17 3.8 
36 60.61 ± 6.86 86.02 ± 2.99 1.4 
37 21.54  ±  5.83 34.35 ± 2.46 1.6 
38 15.95  ±  3.52 13.78 ± 4.37 0.86 
39 83.42  ±  9.08 > 100 > 1.2 
41 12.77  ±  1.61 35.93 ± 4.92 2.8 
42 14.09  ±  2.32 42.30 ± 4.67 3.0 
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49 10.07  ±  3.26 15.40 ± 3.87 1.5 
50 23.95  ±  7.08 32.62 ± 9.71 1.4 
51 1.94  ±  0.51 27.71 ± 1.22 1.3 
53 26.99  ±  4.30 > 100 > 4.7 
54 15.40  ±  1.34 > 100 > 6.5 
55 1.79  ±  0.37 14.72 ± 2.68 8.2 
56 1.13  ±  0.22 12.67 ± 0.70 11.2 
57 1.24  ±  0.31 12.67 ± 0.10 10.2 
58 6.03  ±  1.19 12.65 ± 0.26 2.1 
59 0.19  ±  0.08 11.87 ± 0.43 62.5 
60 2.20  ±  0.33 12.49 ± 0.23 5.7 
 
2.4. Electrochemistry Aspects 
 
Electrochemistry is a useful tool for the design, development and characterization 
of redox-selective molecules and can provide information on their mechanism of action 
[26]. Motivated by this approach, we have successfully described the combined use of 
electrochemistry and biological evaluation to provide insights about the mechanism of 
action of 3-arylamino lapachone [27], as well as selenium [28] and triazole substituted 
[29] quinones. The ever-increasing interest in biologically active quinones has resulted in 
new strategies to decrease toxicity, modulate activity, and direct the compound to the 
target [30]. As such, it is pertinent to continue to explore their synthesis, biological 
activities and redox mechanisms through a combined theoretical and experimental 
approach.  
Most quinones, including intermediary and reduced forms, exist inside 
hydrophobic cell membranes. Consequently, dimethylformamide (DMF) was chosen as 
an aprotic organic solvent for electrochemical studies, because it can mimic the nonpolar 
environment in the cell, where lipid peroxidation, one of the causes of membrane 
fragmentation, normally occurs [24]. We have studied the electrochemical properties of 
nine quinones. These compounds were selected based on their trypanocidal activity; both 
active and inactive variants have been studied to enable an understanding of the main 
qualitative features associated with activity. 
As observed in Figure 2, in general there are two reducible systems (the quinone 
itself and the aryl iodide bond). The electrochemistry of quinones [31] and halogenated 
compounds, mainly aromatic ones (ArX), has been thoroughly investigated [32] on 
several electrodes. For quinones, in aprotic medium,  general equations 1 to 3 are expected 
and the quinone/semiquinone/hydroquinone (Q/SQ•-/H2Q) triad is an important 
component of many redox systems in biology [24,26]. 
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For halides, bi-electronic uptake in aprotic solvents causes rupture of the C-X 
bond, by either a concerted (Eq. (4)) or stepwise mechanism (Eqs. (5) and (6)), followed 
by reduction of the ensuing radical (Eq. (7)) to an anion. The latter is usually protonated 
by residual water to the respective C-H bond [30]. 
 
 
 
The electrochemistry of iodinated quinones where the halogen is directly 
attached to the aromatic ring is less widely reported. In the present case, the reduction 
process of nine iodinated 1,4-naphthoquinones (1,4-NQ), 2, 3, 5, 6, 11, 19, 20, 22 and 55 
was investigated on glassy carbon electrode (GCE), in anhydrous DMF with 0.1 M 
TBAPF6 as the supporting electrolyte and electrochemical data were compared to 
trypanocidal activity. A detailed description of the voltammetric behavior of these novel 
compounds is out of the scope of the present paper. Here we will only consider some 
features relevant to the discussion of the correlation of redox potentials with trypanocidal 
activity. Several of the iodo-naphthoquinones analysed have additional A-ring 
substituents (-OH, -OCH3, and -CH3 groups) and two of them are bis-iodinated (3 and 6).  
All possess an aryl-iodide bond, except 56, which carries a vinyl iodide. Data on the main 
reduction peaks, with an emphasis to the first reduction step, Epc1, appear in Table 2. 
 
Table 3. Major electrochemical parameters of the iodinated quinones (c = 1 mmol L-1), 
using cyclic voltammetry, on GCE, in DMF/TBAPF6, 0.1 mol L
-1,  = 100 mV s-1. 
 
Compound Epc1 (V)  Epc2 (V)  Epc3 (V)  Epa’1 (V)  Epa1 (V)  Epa’2 (V)  Epa2 (V) 
2 -0.535 -1.212 -2.198 - -0.470 - -1.105 
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3 -0.521 -1.514 -1.759 - -0.414 - -1.129 
5 -0.244 -0.903 - - -0.148 - -0.779 
6 -0.216 -0.912 -2.057 - -0.111 - -0.741 
11  -0.625 -1.181 -2.346   -0.550   -1.052 
19 -0.616 -1.312 - - -0.534 - -1.175 
20 -0.593 -1.314 - - -0.514 - -1.146 
22 -0.560 -1.223 -2.242 - -0.493 - -1.119 
55 -0.413 -1.152 -2.880 -0.517 -0.330 -1.204 -1.044 
 
Considering the ease of the reduction related to Epc1 (Figure 2), the compounds 
can be ranked as shown below. Less negative potentials indicate higher electrophilicity: 
6 > 5 > 55 > 3 > 2 > 22 >20 > 19 > 11 (Figure 2). 
 
 
Figure 2. Structures of the naphthoquinones ranked according to data obtained through 
electrochemical studies 
 
The CV profiles (Figure 2) and structural similarities allow the classification of 
the compounds into three main electrochemical classes. 
The first class contains only one compound, 55, and is important as it allows 
comparison of the reduction of aromatic vs. vinylic C-I bonds. Aromatic variants suffer 
much easier reduction (see Epc3), while the ease of reduction of the quinone moiety is 
influenced by the electron withdrawing halogen at C2, being reduced at more positive 
potentials (-0.413 V) than similar C5-iodinated compound 2 (-0.535 V, see table 3). 
The second class comprises compounds with substituents that can hydrogen 
bond (5 and 6). This feature results in easier reduction, presumably due to stabilization of 
the semiquinone (Eq. 1) through hydrogen-bonding. Reduction potentials for 5 and 6 are 
-0.216 V and -0.244 V, respectively; these values are much more positive than for all the 
other quinones. The electrochemical reduction of the C-I, leading to bond cleavage (Eqs. 
4-7) occurs at highly negative potentials (Epc3, Table 2). 
The third class of compounds, 2, 3, 22, 19, 11 and 20, has a different 
electrochemical profile. The first waves for all of them are related to the generation of the 
semiquinone (Eq. 1). With one exception, 22, all of them present an enhanced current at 
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the level of the second reduction wave (Ipc2/Ipc1 > 1), with loss of reversibility (Ipa/Ipc 
< 1). This is related to the reduction of the semiquinone together with the reduction of the 
C-I bonding. In the case of 3, where the current (Ipc2) is the highest, the cleavage of both 
C-I bonds is expected [30] and observed. 
 Comparison of the Epc1 values with trypanocidal activity reveals a trend, with the 
two more electrophilic quinones (5 and 6) being less active than the others. As quinones 
are pro-drugs that need to be activated, being so easily reduced, it is possible that 5 and 6 
suffer reduction fast, before reaching the biological target, leading, thus, to inactivity. 
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Figure 2. Several inversion potentials in the CV of iodinated quinones 2, 3, 5, 6, 11, 19, 
20 and 22 (1 mM) in DMF + TBAPF6 (0.1 M), glassy carbon electrode, cathodic 
direction, potential range: 0.5 V up to –2.5 V,  = 0.1 V s–1. 
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3. Conclusions 
 
The present work shows how a complementary combination of chemical, 
biological and electrochemical approaches can be used for the identification of new lead 
compounds for the treatment of Chagas disease. We have described potent trypanocidal 
naphthoquinones prepared in high efficiency by versatile synthetic methods. Compound 
59, which was prepared in just two steps, has an IC50/24h = 0.19 µM (fifty fold more 
active than benznidazole) and SI = 62.5 and is thus an important starting point for the 
development of a new drug against T. cruzi. In broader terms, the present study provides 
an efficient framework to prepare quinoidal compounds with potent activity against the 
etiological agent of Chagas disease. 
 
4. Experimental Section 
4.1. Chemistry 
 
4.1.1. General procedures 
 
 1,4-Naphthoquinone and 1,4-benzoquinone were purchased from Alfa Aesar and 
Sigma Aldrich, purified via reduced pressure sublimation using a cold finger sublimation 
apparatus (50 °C, 0.9 mbar) and stored in a glovebox to prevent contact with moisture. 
All commercially available naphthoquinones, benzoquinones and further commercial 
chemicals were purchased from Sigma Aldrich, Alfa Aesar, Strem Chemicals and Santa 
Cruz Biotechnology. [RhCptCl2]2 was purchased from Sigma Aldrich. 
 Substrates 9 and 10, as well as derivatives 13 and 14 were obtained by reaction 
with iodomethane and Ag2O in CHCl3 [17]. Substrates 17 and 18
 obtained by oxidation 
of corresponding tetralones with 2-iodobenzoic acid and Oxone [18]. Substrate 24 was 
synthesized by nitration of 1,4-naphthoquinone followed by reduction with SnCl2/FeCl3 
[33]. Substrate 27 was synthesised following our latest report [16]. 2,3-Dimethyl-1,4-
benzoquinone (46), 2-methoxy-1,4-benzoquinone (47) and 2,6-dimethoxy-1,4-
benzoquinone (48) were prepared by oxidation of the corresponding hydroquinones (in 
case of 2,3-dimethyl-1,4-benzoquinone, the hydroxyl groups of the hydroquinone were 
methylated with dimethyl sulfate) with silica supported cerium ammonium nitrate [34]. 
2,3-Dichloro-1,4-benzoquinone (52) was obtained by reaction of 1,4-benzoquinone (35) 
with SOCl2/H2SO4 followed by dehydrogenation with Ag2O [35]. 
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 Starting materials available from commercial suppliers were used as received, 
unless otherwise stated. All reagents requiring purification were purified using standard 
laboratory techniques, according to methods published by Perrin, Armarego, and Perrin 
(Pergamon Press, 1966). Catalytic reactions were run under an atmosphere of dry nitrogen 
or argon; glassware, syringes and needles were either flame dried immediately prior to 
use or placed in an oven (200 °C), for at least 2 h, and allowed to cool either in a desiccator 
or under an atmosphere of nitrogen or argon; liquid reagents, solutions or solvents were 
added via syringe through rubber septa; solid reagents were added inside a glovebox. 
Melting points were obtained on a Thomas Hoover apparatus and are uncorrected. 
Column chromatography was performed on silica gel (SiliaFlash G60 UltraPure 60-200 
µm, 60 Å). Infrared spectra were recorded on an FTIR Spectrometer IR Prestige-21-
Shimadzu. 1H and 13C NMR were recorded at room temperature using a Bruker AVANCE 
DRX200 and DRX400 MHz instrument, in the solvents indicated. Chemical shifts (δ) are 
given in parts per million (ppm) and coupling constants (J) in Hertz (Hz). All assignments 
of NMR spectra were based on 2D NMR data (DEPT-135, COSY, HSQC and HMBC). 
Mass spectra were recorded using a Brüker Daltonics FT-ICRMS Apex 4e 7.0T FT-MS 
(ESI+ mode) and Shimadzu GCMS QP2010+ (EI+ mode). Infrared spectra were recorded 
on a Perkin Elmer Spectrum One FTIR spectrometer as thin films or solids compressed 
on a diamond plate. Data were processed employing Bruker Data Analysis software 
version 4.0. Compounds were named following IUPAC rules as applied by 
ChemBioDraw Ultra (version 12.0). 
4.1.2. 5-Hydroxy-6-iodo-1,4-naphthoquinone (5). Yield: 88%; m.p. (°C) = 
179.8-180.1; red crystals. IR (solid, cm-1) ν: 3021 (w), 1698 (s), 1270 (m), 830 (m); 
HRMS (EI+): 299.9280 [M]+. Cald. for [C10H5IO3]: 299.9283; 
1H NMR (400 MHz, 
CDCl3) δ: 12.73 (s, O-H), 8.15 (d, J = 8.0 Hz, C6-H), 7.33 (d, J = 8.0 Hz, C5-H), 6.96 (s, 
C2-H,C3-H); 13C NMR (100 MHz, CDCl3) δ: 190.0 (C4), 183.8 (C1), 160.1 (C5), 146.1 
(C7), 139.8 (C3), 138.0 (C2), 131.5 (C8a), 120.1 (C8), 114.2 (C4a), 94.9 (C6-I). 
4.1.3. 5-Hydroxy-6,8-diiodo1,4-naphthoquinone (6). Yield: 82%; m.p. (°C) = 
164.3-165.8; purple crystals. IR (solid, cm-1) ν: 3002 (w), 1613 (s), 1211 (m), 911 (m); 
HRMS (EI+): 425.8241 [M]+. Cald. for [C10H4I2O3]: 425.8250; 
1H NMR (500 MHz, 
CDCl3) δ: 13.54 (s, O-H), 8.80 (s, C7-H), 7.04 (d, J = 10.2 Hz, C2-H), 6.96 (d, J = 10.2 
Hz, C3-H); 13C NMR (125 MHz, CDCl3) δ: 189.2 (C4), 182.0 (C1), 161.7 (C5), 158.5 
(C7), 140.4 (C2), 136.5 (C3), 130.0 (C8a), 115.8 (C4a), 96.0 (C6-I), 83.0 (C8-I). 
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4.1.4. 5-Hydroxy-6-iodo-2-methyl-1,4-naphthoquinone (8). Yield: 85%; m.p. 
(°C) = 125.1-125.9; red crystals. IR (solid, cm-1) ν: 3048 (w), 1687 (s), 1198 (m), 854 
(m); MS (EI+): 313.9 [M]+. Cald. for [C11H7IO3]: 313.9; 
1H NMR (400 MHz, CDCl3) δ: 
12.82 (s, 1H), 8.11 (d, J = 7.9 Hz, C7-H), 7.35 (d, J = 7.9 Hz, C8-H), 6.81 (s, C3-H), 2.19 
(s, C9-H3). 
13C NMR (100 MHz, CDCl3) δ: 189.9 (C4), 184.3 (C1), 159.9 (C5-OH), 150.0 
(C2), 145.6 (C7), 134.8 (C3), 131.9 (C8a), 120.3 (C8), 114.4(C4a), 94.4 C6-I, 16.5 (C9). 
4.1.5. 6-Iodo-5-methoxy-1,4-naphthoquinone (13). Yield: 91%; m.p. (°C) = 
152.3-152.8; yellow powder. IR (solid, cm-1) ν: 3014 (w), 1699 (s), 1199 (m), 867 (m); 
MS (EI+): 313.9 [M]+. Cald. for [C11H7IO3]: 313.9; 
1H NMR (400 MHz, CDCl3) δ: 8.24 
(d, J = 8.2 Hz, C7-H), 7.65 (d, J = 8.2 Hz, C8-H), 6.95 (d, J = 10.3 Hz, C2-H), 6.90 (d, J 
= 10.3 Hz, C3-H), 3.93 (s, C9-H3). 
13C NMR (100 MHz, CDCl3) δ: 184.4 (C1), 183.3 
(C4), 159.2 (C5), 144.7 (C7), 139.9 (C3), 136.9 (C2), 134.1 (C8a), 124.2 (C8), 124.1 
(C4a), 104.2 (C6-I), 61.8 (C9). 
4.1.6. 6-Iodo-5-methoxy-2-methyl-1,4-naphthoquinone (14). Yield: 92%; m.p. 
(°C) = 117.3-118.1; yellow powder. IR (solid, cm-1) ν: 2985 (w), 1689 (s), 1321 (m), 902 
(m); MS (EI+): 327.9 [M]+. Cald. for [C12H9IO3]: 327.9; 
1H NMR (400 MHz, CDCl3) δ: 
8.19 (d, J = 8.2 Hz, C7-H), 7.65 (d, J = 8.2 Hz, C8-H), 6.76 (s, C3-H), 3.91 (s, C10-H3), 
2.17 (s, C9-H3). ). 
13C NMR (100 MHz, CDCl3) δ: 185.0 (C1), 183.3 (C4), 158.9 (C5), 
146.3 (C2), 144.3 (C7), 136.9 (C3), 134.4 (C8a), 124.4 (C8), 124.3 (C4a), 103.8 (C6-I), 
61.8 (C10), 15.9 (C9). 
4.1.7. 5-Amino-6-iodo-1,4-naphthoquinone (25). Yield: 41%; m.p. (°C) = 
181.2-182.9, purple powder. IR (solid, cm-1) ν: 3078 (w), 1720 (s), 1380 (m), 923 (m); 
HRMS (EI+): 298.9433 [M]+. Cald. for [C10H6INO2]: 298.9443; 
1H NMR (400 MHz, 
CDCl3) δ: 8.03 (d, J = 8.0 Hz, C7-H), 7.15 (d, J = 8.0 Hz, C8-H), 6.90 (d, J = 10.3 Hz, 
C3-H), 6.86 (d, J = 10.3 Hz, C2-H); 13C NMR (100 MHz, CDCl3) δ: 186.65 (C4), 184.97 
(C1), 149.21 (C5), 144.79 (C7), 140.05 (C3), 137.20 (C2), 132.92 (C8a), 117.45 (C8), 
111.89 (C4a), 95.06 (C6-I). 
4.1.8. 2,6-Diiodo-3,5-dimethoxy-1,4-benzoquinone (51). Yield: 91%; m.p. (°C) 
= 160.2-160.9; red crystals. IR (solid, cm-1) ν: 2947 (w), 1667 (s), 1266 (s), 924 (s); 
HRMS (EI+): 261.9493 [M]+. Cald. for [C8H6I2O4]: 419.8355; 
1H NMR (500 MHz, 
CDCl3) δ: 4.16 (s, C7-H6); 13C NMR (125 MHz, CDCl3) δ: 175.2 (C1), 171.2 (C4), 160.4 
(C2,C6), 98.1 (C3,C5), 61.6 (C7). 
4.1.9. (E)-5-Styrylnaphthalene-1,4-dione (59). Yield: 51%; m.p.(°C): 140.8-
141.9; red solid. IR (solid, cm-1) ν: 2956 (w), 1717 (s), 1632 (s), 1278 (m), 1100 (m), 790 
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(m); HRMS(EI+): 260.0822. Cald. for [C18H12O2]
+: 260.0837; 1H NMR (500 MHz, 
CDCl3) δ: 8.30 (d, J = 16.1 Hz, C9-H), 8.10 (dt, J = 7.6, 1.2 Hz, C8-H), 7.98 (dd, J = 
7.9, 0.8 Hz, C6-H), 7.72 (t, J = 7.8 Hz, C7-H), 7.62 – 7.60 (m, 2H), 7.43 – 7.37 (m, 2H), 
7.35 – 7.29 (m, 1H), 7.06 (d, J = 16.2 Hz, C10-H), 6.95 (d, J = 1.0 Hz,C2-H, C3-H). 13C 
NMR (125 MHz, CDCl3) δ: 187.0 (C4), 185.2 (C1), 140.5 (C2), 140.2 (C5), 137.1 (C8a), 
136.9 (C3), 133.5 (C10), 133.5 (C6), 133.3 (C7), 128.8 (C13, C15), 128.3 (C14), 127.9 
(C4a), 127.7 (C9), 127.1 (C12, C16), 126.5 (C8). 
 
4.2. Crystallographic data 
 
X-ray diffraction data collection for three compounds were performed on an 
Enraf-Nonius Kappa-CCD diffractometer (95 mm CCD camera on κ-goniostat) using 
graphite monochromated MoK_radiation (0.71073 Å), at room temperature. Data 
collection was carried out using the COLLECT software [36] up to 50° in 2θ.  Integration 
and scaling of the reflections, correction for Lorentz and polarization effects were 
performed with the HKL DENZO-SCALEPACK system of programs [37]. The structure 
of the compounds was solved by direct methods with SHELXS-97 [38]. The models were 
refined by full-matrix least squares on F2 using the SHELXL-97 [39]. The program 
ORTEP-3 [40] was used for graphic representation and the program WINGX [41] to 
prepare materials for publication. All H atoms were located by geometric considerations 
(C-H = 0.93-0.97; O-H = 0.82 Å) and refined as riding with Uiso(H) = 1.5Ueq(C-methyl) 
or 1.2Ueq(other). Crystallographic data for the structures were deposited in the 
Cambridge Crystallographic Data Centre, with numbers CCDC 1526294, 1526293 and 
1526364. 
 
4.3. Animals 
 
Albino Swiss mice were employed for the trypanocidal and cytotoxicity assays, 
in accordance to the guidelines of the Colégio Brasileiro de Experimentação Animal 
(COBEA), and these were performed under biosafety conditions. All animal 
experimentation procedures were approved by the Comissão de Ética em Experimentação 
Animal (CEUA/Fiocruz), license LW 16/13. 
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4.4. Trypanocidal Assay 
 
The experiments were performed with the Y strain of T. cruzi [42]. Stock solutions 
of the compounds were prepared in dimethylsulfoxide (DMSO), with the final 
concentration of the latter in the experiments never exceeding 0.1%. Preliminary 
experiments showed that at concentrations of up to 0.5%, DMSO has no deleterious effect 
on the parasites [43]. Bloodstream trypomastigotes were obtained from infected Albino 
Swiss mice at the peak of parasitemia by differential centrifugation. The parasites were 
resuspended to a concentration of 10x106 cells/mL in DMES medium. This suspension 
(100 μL) was added to the same volume of each of the compounds, which had been 
previously prepared at twice the desired final concentrations. The incubation was 
performed in 96-well microplates (Nunc Inc., Rochester, USA) at 37°C for 24 h. 
Benznidazole (Lafepe, Brazil), the standard drug for treatment of chagasic patients, was 
used as control. Cell counts were performed in a Neubauer chamber, and the activity of 
the compounds corresponding to the concentration that led to 50% lysis of the parasites 
was expressed as the IC50/24 h. 
 
4.5. Cytotoxicity to mammalian cells 
 
The cytotoxicity assays were performed using primary cultures of peritoneal 
macrophages obtained from Albino Swiss mice.  For the experiments, 2.5x104 cells in 
200 µL of RPMI-1640 medium (pH 7.2 plus 10% foetal bovine serum and 2 mM 
glutamine) were added to each well of a 96-well microtiter plate and incubated for 24 h 
at 37°C. The treatment of the cultures was performed in fresh supplemented medium (200 
µL/well) for 24 h at 37°C. After this period, 110 µL of the medium was discarded and 10 
µL of PrestoBlue (Invitrogen) was added to complete the final volume of 100 µL. Thus, 
the plate was incubated for 2 h and the measurement was performed at 560 and 590 nm, 
as recommended by the manufacturer. The results were expressed as the difference in the 
percentage of reduction between treated and untreated cells being the LC50 value, 
corresponding to the concentration that leads to damage of 50% of the mammalian cells 
[25]. 
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4.6. Electrochemical studies 
 
Cyclic voltammetry (CV) experiments were performed with a conventional three 
electrode cell in an Autolab PGSTAT-30 potentiostat (Echo Chemie, Utrecht, the 
Netherlands) coupled to a PC microcomputer, using GPES 4.9 software. The working 
electrode was a glassy carbon (GC) BAS (d = 3 mm), the counter electrode was a Pt wire 
and the reference electrode an Ag|AgCl, Cl− (saturated), all contained in a one-
compartment electrochemical cell with a volumetric capacity of 5 mL. The GC electrode 
was cleaned up by polishing with alumina on a polishing felt (BAS polishing kit). The 
solvent used in aprotic media studies was extra dry N,N-dimethylformamide (99.8%) 
acquired from Acros Organics. In CV experiments, the scan rate varied from 10 to 1000 
mV s-1. Electrochemical reduction and oxidation were performed in aprotic media (DMF 
+ TBAPF6 0.1 mol L
-1) at room temperature (25 ± 2 °C). Each compound (1 x 10-3 mol 
L-1) was added to the supporting electrolyte and the solution was deoxygenated with argon 
before the measurements by cyclic voltammetry, in different potential intervals.  
 
Appendix A. Supplementary data 
 
Supplementary data related to this article can be found at DOI 
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